Skip to content
Teethgrinder – Lifestyle
Author:
Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
October 2, 2026
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 15, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Vera Therapeutics to Participate at Upcoming Investor Conferences
September 1, 2026
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 7, 2026
1
2
Next Page
→